BPL-003 (mebufotenin benzoate) vs Lysergide tartrate (LSD)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: 5-HT2A receptor · full Major Depressive Disorder pipeline

BPL-003 (mebufotenin benzoate)

Developed by AtaiBeckley Inc. and partners

Phase 2 in Major Depressive Disordersmall molecule
Partial signal

NCT05870540 · Phase 2 · completed

The core study randomized 196 participants and used a masked design with an active-placebo comparator; its primary endpoint was the clinical depression measure MADRS. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: November 2026 · NCT05660642 (registry estimate)

Reported efficacy

Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) (4 weeks): MADRS change from baseline at Day 29: 12 mg BPL-003 -11.1 points vs -5.8 points for 0.3 mg comparator arm (p=0.0038); 8 mg BPL-003 -12.1 points vs 0.3 mg comparator (p=0.0025). (met)

Result source: NCT05870540

Lysergide tartrate (LSD) · DT120

Developed by Definium Therapeutics

Phase 3 in Major Depressive Disordersmall molecule
Reliable signal

NCT06941844 · Phase 3 · active, not recruiting

Participants were randomized and the study was triple-blinded (participant, investigator, and outcomes assessor) against a placebo comparator, which minimizes bias from expectation effects common in psychedelic trials. The primary endpoint, change in a validated clinical depression severity scale (MADRS) at Week 6, showed a large and statistically significant improvement for the drug versus placebo (p<0.0001), meeting the pre-specified comparison in the favorable direction.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: September 2027 · NCT07592689 (registry estimate)

Reported efficacy

Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6 (Baseline to Week 6): Emerge (NCT06941844), primary endpoint LS mean change in MADRS total score at Week 6: DT120 ODT 100 µg -13.3 vs placebo -5.2; LS mean difference -8.1 points; p<0.0001. (met)

Result source: NCT06941844

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBPL-003 (mebufotenin benzoate)Lysergide tartrate (LSD)
MADRS, change (acute)-11.1 vs -5.8avs 0.3 mg comparator arm12 mg BPL-003 · wk 4.142857NCT05870540
1 other result
  • -12.1 vs -5.8 8 mg BPL-003 · wk 4.142857 · Phase 2 · primary NCT05870540
—Trial running · NCT06941844
CGI-S, change (acute)—Not reported—Trial running · NCT06941844
MADRS response—Not reported—Trial running · NCT06941844
MADRS remission—Not reported—Trial running · NCT06941844
Relapse (% of patients)—Not reported—Trial running · NCT06941844

MADRS, change (acute)

BPL-003 (mebufotenin benzoate)
-11.1 vs -5.8avs 0.3 mg comparator arm12 mg BPL-003 · wk 4.142857NCT05870540
1 other result
  • -12.1 vs -5.8 8 mg BPL-003 · wk 4.142857 · Phase 2 · primary NCT05870540
Lysergide tartrate (LSD)
—Trial running · NCT06941844

CGI-S, change (acute)

BPL-003 (mebufotenin benzoate)
—Not reported
Lysergide tartrate (LSD)
—Trial running · NCT06941844

MADRS response

BPL-003 (mebufotenin benzoate)
—Not reported
Lysergide tartrate (LSD)
—Trial running · NCT06941844

MADRS remission

BPL-003 (mebufotenin benzoate)
—Not reported
Lysergide tartrate (LSD)
—Trial running · NCT06941844

Relapse (% of patients)

BPL-003 (mebufotenin benzoate)
—Not reported
Lysergide tartrate (LSD)
—Trial running · NCT06941844
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Lysergide tartrate (LSD)
Emerge (NCT06941844), primary endpoint LS mean change in MADRS total score at Week 6: DT120 ODT 100 µg -13.3 vs placebo -5.2; LS mean difference -8.1 points; p<0.0001. NCT06941844 · Phase 3 · design grade: strong · publication or press release
IDS-SR (self-rated): -3.9 low-dose vs -11.8 high-dose, diff -7.9, p=0.059 (not significant). IDS-C (clinician-rated): -3.6 low-dose vs -12.9 high-dose, diff -9.2, p=0.023 corrected <0.05 (significant). 31 patients low-dose, 30 high-dose. NCT03866252 · Phase 2 · design grade: moderate · publication or press release

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

BPL-003 (mebufotenin benzoate)

MADRS -11.1 vs -5.8 0.3 mg comparator arm score @ 4.142857wk12 mg BPL-003
absolute change · score
NCT05870540 · Phase 2 · sponsor-reported, not registry data
show 1 more result
-12.1 vs -5.8 0.3 mg comparator score @ 4.142857wk8 mg BPL-003
NCT05870540 · Phase 2 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BPL-003 (mebufotenin benzoate)'s landscape · Lysergide tartrate (LSD)'s landscape